

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3969610

| | |
|---|--|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| | |
| Name | Execution Date |
| ARBEL DAVID TADMOR | 02/02/2016 |
| JOHN CHRISTOPHER CASTLE | 02/06/2016 |
| MARTIN LÖWER | 01/28/2016 |
| RECEIVING PARTY DATA | |
| Name: | TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH |
| Street Address: | FREILIGRATHSTRASSE 12 |
| City: | MAINZ |
| State/Country: | GERMANY |
| Postal Code: | 55131 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 14787110 |
| CORRESPONDENCE DATA | |
| Fax Number: | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Email: | mhmpto@mcandrews-ip.com |
| Correspondent Name: | MCANDREWS HELD & MALLOY, LTD. |
| Address Line 1: | 500 W MADISON STREET |
| Address Line 2: | 34TH FLOOR |
| Address Line 4: | CHICAGO, ILLINOIS 60661 |
| ATTORNEY DOCKET NUMBER: | 60143US01 |
| NAME OF SUBMITTER: | GEORGE T. WU. |
| SIGNATURE: | /George T. Wu/ |
| DATE SIGNED: | 07/20/2016 |
| Total Attachments: 9 | |
| source=60143US01_assignment_Tadmor_Castle_Lower_Executed#page1.tif | |
| source=60143US01_assignment_Tadmor_Castle_Lower_Executed#page2.tif | |

source=60143US01_assignment_Tadmor_Castle_Lower_Executed#page3.tif
source=60143US01_assignment_Tadmor_Castle_Lower_Executed#page4.tif
source=60143US01_assignment_Tadmor_Castle_Lower_Executed#page5.tif
source=60143US01_assignment_Tadmor_Castle_Lower_Executed#page6.tif
source=60143US01_assignment_Tadmor_Castle_Lower_Executed#page7.tif
source=60143US01_assignment_Tadmor_Castle_Lower_Executed#page8.tif
source=60143US01_assignment_Tadmor_Castle_Lower_Executed#page9.tif

PATENT ASSIGNMENT

Attorney Case Number: 60143US01

U.S. Serial Number: 14/787,110

WHEREAS, we, Arbel David Tadmor, John Christopher Castle and Martin Löwer (collectively referred to hereinafter as the "Assignors") have made new and useful inventions and improvements disclosed in a United States patent application entitled "PREDICTING IMMUNOGENICITY OF T CELL EPITOPES" filed on October 26, 2015, in the United States Patent and Trademark Office as Serial No. 14/787,110; which is a 371 of the international patent application entitled "INDIVIDUALIZED VACCINES FOR CANCER" filed on May 7, 2014, as International Application No. PCT/EP2014/001232 and in any and all other (provisional or non-provisional) applications both United States and foreign based thereon that claim priority thereto, which the undersigned may file, either solely or jointly with others, on said invention or improvements, and in any and all Letters Patent of the United States and foreign countries, which may be obtained on any of said applications, and in any continuation, continuation-in-part, divisional, reexamination, renewal, substitutions, reissue or extension of such applications or patents, and further assigns to said assignee the priority right provided by the International Convention, treaties or otherwise (collectively referred to hereinafter as the "Applications").

WHEREAS, TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH, Freiligrathstrasse 12, 55131 Mainz, Germany (referred to hereinafter as the "Assignees") is desirous of acquiring the title, rights, and privileges hereinafter recited.

NOW, THEREFORE, in exchange for good and valuable consideration in hand paid, the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Assignors hereby assign to the Assignee, its successors and assigns, the entire right, title and interest in and to said Applications and the inventions and improvements disclosed therein, and in any and all other (provisional or non-provisional) applications, both United States and foreign, based thereon or that claim priority thereto, including any continuation, continuation-in-part, or divisional application that the Assignors may file, either solely or jointly with others, and in any and all Letters Patent of the United States and foreign countries that may be obtained on any of said Applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents, and every priority right that is or may be predicated upon or arise from said inventions, improvements, applications, and Letters Patent.

The Assignors hereby authorize the Assignee, its successors and assigns, to file patent applications in any or all countries for any or all of said inventions and improvements in our name or in the name of the Assignee, its successors and assigns, or otherwise as said Assignee, its successors and assigns, may deem advisable, under the International Convention or otherwise. The Assignors hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent to said Assignee, its successors and assigns.

The Assignors warrant to be the owner of the entire right, title and interest in said invention or improvements and to have the right to make this Assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The Assignors hereby agree, upon the request and at the expense of said Assignee, its successors and assigns, to execute any and all continuation, continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination, or extension of any Letters Patent that may be granted upon said Applications, that said Assignee, its successors or assigns may deem necessary or expedient; and to cooperate to the best of the ability of the Assignors with said Assignee, its successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all acts necessary to obtain said Letters Patent in the United States and foreign countries, and vest all rights therein hereby conveyed in the Assignee, its successors and assigns, whereby said Letters Patent will be held and enjoyed by the said Assignee, its successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors if this Assignment had not been made.

This Assignment shall be binding upon and shall inure to the benefit of the Assignee and Assignors and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

[SIGNATURE PAGE FOLLOWS]

EXECUTED this 2 day of Feb, 2016.



Arbel David Tadmor

WITNESSED by Carina Walter this 2 day of Feb, 2016.

WITNESSED by Martin Löwer this 2 day of Feb, 2016.

EXECUTED this _____ day of _____, 2016.

John Christopher Castle

WITNESSED by _____ this _____ day of _____, 2016.

WITNESSED by _____ this _____ day of _____, 2016.

EXECUTED this _____ day of _____, 2016.

Martin Löwer

WITNESSED by _____ this _____ day of _____, 2016.

WITNESSED by _____ this _____ day of _____, 2016.

PATENT ASSIGNMENT

Attorney Case Number: 60143US01

U.S. Serial Number: 14/787,110

WHEREAS, we, Arbel David Tadmor, John Christopher Castle and Martin Löwer (collectively referred to hereinafter as the "Assignors") have made new and useful inventions and improvements disclosed in a United States patent application entitled "PREDICTING IMMUNOGENICITY OF T CELL EPITOPES" filed on October 26, 2015, in the United States Patent and Trademark Office as Serial No. 14/787,110; which is a 371 of the international patent application entitled "INDIVIDUALIZED VACCINES FOR CANCER" filed on May 7, 2014, as International Application No. PCT/EP2014/001232 and in any and all other (provisional or non-provisional) applications both United States and foreign based thereon that claim priority thereto, which the undersigned may file, either solely or jointly with others, on said invention or improvements, and in any and all Letters Patent of the United States and foreign countries, which may be obtained on any of said applications, and in any continuation, continuation-in-part, divisional, reexamination, renewal, substitutions, reissue or extension of such applications or patents, and further assigns to said assignee the priority right provided by the International Convention, treaties or otherwise (collectively referred to hereinafter as the "Applications").

WHEREAS, TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH, Freiligrathstrasse 12, 55131 Mainz, Germany (referred to hereinafter as the "Assignees") is desirous of acquiring the title, rights, and privileges hereinafter recited.

NOW, THEREFORE, in exchange for good and valuable consideration in hand paid, the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Assignors hereby assign to the Assignee, its successors and assigns, the entire right, title and interest in and to said Applications and the inventions and improvements disclosed therein, and in any and all other (provisional or non-provisional) applications, both United States and foreign, based thereon or that claim priority thereto, including any continuation, continuation-in-part, or divisional application that the Assignors may file, either solely or jointly with others, and in any and all Letters Patent of the United States and foreign countries that may be obtained on any of said Applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents, and every priority right that is or may be predicated upon or arise from said inventions, improvements, applications, and Letters Patent.

The Assignors hereby authorize the Assignee, its successors and assigns, to file patent applications in any or all countries for any or all of said inventions and improvements in our name or in the name of the Assignee, its successors and assigns, or otherwise as said Assignee, its successors and assigns, may deem advisable, under the International Convention or otherwise. The Assignors hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent to said Assignee, its successors and assigns.

The Assignors warrant to be the owner of the entire right, title and interest in said invention or improvements and to have the right to make this Assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The Assignors hereby agree, upon the request and at the expense of said Assignee, its successors and assigns, to execute any and all continuation, continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination, or extension of any Letters Patent that may be granted upon said Applications, that said Assignee, its successors or assigns may deem necessary or expedient; and to cooperate to the best of the ability of the Assignors with said Assignee, its successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all acts necessary to obtain said Letters Patent in the United States and foreign countries, and vest all rights therein hereby conveyed in the Assignee, its successors and assigns, whereby said Letters Patent will be held and enjoyed by the said Assignee, its successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors if this Assignment had not been made.

This Assignment shall be binding upon and shall inure to the benefit of the Assignee and Assignors and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

[SIGNATURE PAGE FOLLOWS]

EXECUTED this _____ day of _____, 2016.

Arbel David Tadmor

WITNESSED by _____ this _____ day of _____, 2016.

WITNESSED by _____ this _____ day of _____, 2016.

EXECUTED this 6 day of FEB, 2016.



John Christopher Castle

WITNESSED by _____ this _____ day of _____, 2016.

WITNESSED by _____ this _____ day of _____, 2016.

EXECUTED this _____ day of _____, 2016.

Martin Löwer

WITNESSED by _____ this _____ day of _____, 2016.

WITNESSED by _____ this _____ day of _____, 2016.

PATENT ASSIGNMENT

Attorney Case Number: 60143US01

U.S. Serial Number: 14/787,110

WHEREAS, we, Arbel David Tadmor, John Christopher Castle and Martin Löwer (collectively referred to hereinafter as the "Assignors") have made new and useful inventions and improvements disclosed in a United States patent application entitled "PREDICTING IMMUNOGENICITY OF T CELL EPITOPES" filed on October 26, 2015, in the United States Patent and Trademark Office as Serial No. 14/787,110; which is a 371 of the international patent application entitled "INDIVIDUALIZED VACCINES FOR CANCER" filed on May 7, 2014, as International Application No. PCT/EP2014/001232 and in any and all other (provisional or non-provisional) applications both United States and foreign based thereon that claim priority thereto, which the undersigned may file, either solely or jointly with others, on said invention or improvements, and in any and all Letters Patent of the United States and foreign countries, which may be obtained on any of said applications, and in any continuation, continuation-in-part, divisional, reexamination, renewal, substitutions, reissue or extension of such applications or patents, and further assigns to said assignee the priority right provided by the International Convention, treaties or otherwise (collectively referred to hereinafter as the "Applications").

WHEREAS, TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH, Freiligrathstrasse 12, 55131 Mainz, Germany (referred to hereinafter as the "Assignees") is desirous of acquiring the title, rights, and privileges hereinafter recited.

NOW, THEREFORE, in exchange for good and valuable consideration in hand paid, the receipt, adequacy, and sufficiency of which are hereby acknowledged, the Assignors hereby assign to the Assignee, its successors and assigns, the entire right, title and interest in and to said Applications and the inventions and improvements disclosed therein, and in any and all other (provisional or non-provisional) applications, both United States and foreign, based thereon or that claim priority thereto, including any continuation, continuation-in-part, or divisional application that the Assignors may file, either solely or jointly with others, and in any and all Letters Patent of the United States and foreign countries that may be obtained on any of said Applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents, and every priority right that is or may be predicated upon or arise from said inventions, improvements, applications, and Letters Patent.

The Assignors hereby authorize the Assignee, its successors and assigns, to file patent applications in any or all countries for any or all of said inventions and improvements in our name or in the name of the Assignee, its successors and assigns, or otherwise as said Assignee, its successors and assigns, may deem advisable, under the International Convention or otherwise. The Assignors hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent to said Assignee, its successors and assigns.

The Assignors warrant to be the owner of the entire right, title and interest in said invention or improvements and to have the right to make this Assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

The Assignors hereby agree, upon the request and at the expense of said Assignee, its successors and assigns, to execute any and all continuation, continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination, or extension of any Letters Patent that may be granted upon said Applications, that said Assignee, its successors or assigns may deem necessary or expedient; and to cooperate to the best of the ability of the Assignors with said Assignee, its successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all acts necessary to obtain said Letters Patent in the United States and foreign countries, and vest all rights therein hereby conveyed in the Assignee, its successors and assigns, whereby said Letters Patent will be held and enjoyed by the said Assignee, its successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the Assignors if this Assignment had not been made.

This Assignment shall be binding upon and shall inure to the benefit of the Assignee and Assignors and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

[SIGNATURE PAGE FOLLOWS]

EXECUTED this _____ day of _____, 2016.

Arbel David Tadmor

WITNESSED by _____ this _____ day of _____, 2016.

WITNESSED by _____ this _____ day of _____, 2016.

EXECUTED this _____ day of _____, 2016.

John Christopher Castle

WITNESSED by _____ this _____ day of _____, 2016.


WITNESSED by _____ this _____ day of _____, 2016.

EXECUTED this 28 day of JAN, 2016.



Martin Löwer

WITNESSED by  this 28 day of Jan, 2016.

WITNESSED by  this 28 day of Jan, 2016.